Medigene Inkomsten in het verleden

Verleden criteriumcontroles 0/6

Medigene has been growing earnings at an average annual rate of 11.2%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been growing at an average rate of 7.5% per year.

Belangrijke informatie

11.2%

Groei van de winst

11.4%

Groei van de winst per aandeel

Biotechs Groei van de industrie-14.6%
Inkomstengroei7.5%
Rendement op eigen vermogen-81.0%
Nettomarge-214.0%
Laatste winstupdate30 Jun 2024

Recente prestatie-updates uit het verleden

Recent updates

Here's Why We're Watching Medigene's (ETR:MDG1) Cash Burn Situation

Jan 03
Here's Why We're Watching Medigene's (ETR:MDG1) Cash Burn Situation

The Strong Earnings Posted By Medigene (ETR:MDG1) Are A Good Indication Of The Strength Of The Business

Aug 12
The Strong Earnings Posted By Medigene (ETR:MDG1) Are A Good Indication Of The Strength Of The Business

Medigene AG (ETR:MDG1) Analysts Just Trimmed Their Revenue Forecasts By 41%

Aug 10
Medigene AG (ETR:MDG1) Analysts Just Trimmed Their Revenue Forecasts By 41%

We're Hopeful That Medigene (ETR:MDG1) Will Use Its Cash Wisely

Mar 24
We're Hopeful That Medigene (ETR:MDG1) Will Use Its Cash Wisely

Here's Why We're Not Too Worried About Medigene's (ETR:MDG1) Cash Burn Situation

Nov 29
Here's Why We're Not Too Worried About Medigene's (ETR:MDG1) Cash Burn Situation

This Is Why Shareholders May Want To Hold Back On A Pay Rise For Medigene AG's (ETR:MDG1) CEO

Jun 17
This Is Why Shareholders May Want To Hold Back On A Pay Rise For Medigene AG's (ETR:MDG1) CEO

We're Keeping An Eye On Medigene's (ETR:MDG1) Cash Burn Rate

Mar 29
We're Keeping An Eye On Medigene's (ETR:MDG1) Cash Burn Rate

How Much Did Medigene's(ETR:MDG1) Shareholders Earn From Share Price Movements Over The Last Three Years?

Feb 16
How Much Did Medigene's(ETR:MDG1) Shareholders Earn From Share Price Movements Over The Last Three Years?

How Much Is Medigene's (ETR:MDG1) CEO Getting Paid?

Dec 23
How Much Is Medigene's (ETR:MDG1) CEO Getting Paid?

Opbrengsten en kosten

Hoe Medigene geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.


Inkomsten en omzetgeschiedenis

XTRA:MDG1 Opbrengsten, kosten en inkomsten (EUR Millions )
DatumInkomstenInkomstenG+A UitgavenR&D-uitgaven
30 Jun 247-16913
31 Mar 247-16912
31 Dec 236-16912
30 Sep 238-23911
30 Jun 239-29810
31 Mar 2320-1999
31 Dec 2231-8108
30 Sep 22311108
30 Jun 223110109
31 Mar 22210810
31 Dec 2110-10711
30 Sep 2110-16714
30 Jun 219-22717
31 Mar 218-25820
31 Dec 208-29922
30 Sep 209-25923
30 Jun 209-23823
31 Mar 2010-21823
31 Dec 1911-20823
30 Sep 199-23820
30 Jun 199-23819
31 Mar 198-19818
31 Dec 188-21817
30 Sep 188-18817
30 Jun 188-16716
31 Mar 188-16816
31 Dec 178-16815
30 Sep 178-14915
30 Jun 178-171014
31 Mar 178-121013
31 Dec 167-91012
30 Sep 166-81010
30 Jun 167-789
31 Mar 167-1189
31 Dec 157-1389
30 Sep 1511-1178
30 Jun 1511-978
31 Mar 1513-778
31 Dec 1413-677
30 Sep 1410-887
30 Jun 149-787
31 Mar 148-986
31 Dec 138-1087

Kwaliteitswinsten: MDG1 is currently unprofitable.

Groeiende winstmarge: MDG1 is currently unprofitable.


Analyse vrije kasstroom versus winst


Analyse van de winstgroei in het verleden

Winsttrend: MDG1 is unprofitable, but has reduced losses over the past 5 years at a rate of 11.2% per year.

Versnelling van de groei: Unable to compare MDG1's earnings growth over the past year to its 5-year average as it is currently unprofitable

Winst versus industrie: MDG1 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-20.8%).


Rendement op eigen vermogen

Hoge ROE: MDG1 has a negative Return on Equity (-81.04%), as it is currently unprofitable.


Rendement op activa


Rendement op geïnvesteerd vermogen


Ontdek sterk presterende bedrijven uit het verleden